82258-55-7

Upstream product

• 996-82-7 sodium diethylmalonate 
• 26420-79-1 1-chloro-3-benzyloxypropane 
• 54314-84-0 1-[(3-bromopropoxy)methyl]-benzene 
• 105-53-3 diethyl malonate 
• 5375-00-8 3-benzyloxypropyl iodide 
• 100-44-7 benzyl chloride 
• 98518-10-6 3-benzyloxy-1-propanol methanesulfonate 
• 4799-68-2 3-benzyloxypropan-1-ol 

Downstream Products

• 120712-73-4 1-Benzyloxy-9-brom-4,4-nonandicarbonsaeure-diethylester 
• 120712-68-7 1-Benzyloxy-21-brom-4,4,10,16-henicosantetracarbonsaeure-tetraethylester 
• 132970-27-5 2-(3-(benzyloxy)propyl)propane-1,3-diol 
• 1399219-88-5 (1R,4S)-4-(5-(benzyloxy)-1-ethoxy-2-(ethoxycarbonyl)-1-oxopentan-2-yl)cyclobut-2-enecarboxylic acid 
• 1356686-57-1 (1R,4R)-4-(5-(benzyloxy)-1-ethoxy-2-(ethoxycarbonyl)-1-oxopentan-2-yl)cyclobut-2-enecarboxylic acid 
• 1399220-09-7 diethyl 2-(3-(benzyloxy)propyl)-2-((1S,4S)-4-((2 (trimethylsilyl)ethoxy)carbonyl)cyclobut-2-en-1-yl)malonate 
• 1399219-95-4 diethyl 2-(3-(benzyloxy)propyl)-2-((1R,4S)-4-((2-(trimethylsilyl)ethoxy)carbonyl)cyclobut-2-en-1-yl)malonate 
• 1356685-91-0 (1S,4R)-4-(5-(benzyloxy)-1-ethoxy-2-(ethoxycarbonyl)-1-oxopentan-2-yl)cyclobut-2-enecarboxylic acid 
• 854843-33-7 (3-benzyloxy-propyl)-chloro-malonic acid 
• 854658-43-8 5-benzyloxy-2-chloro-pentanoic acid 
• 107688-37-9 3-Benzyloxycarbonyl-5-(3-methansulfonoxypropyl)-1,2,4,5,6,7,8,9-octahydro-3H-azecino<5,4-b>indol-8-carbonsaeuremethylester 
• 107704-40-5 3-Benzyloxycarbonyl-5-(3-benzyloxypropyl)-1,2,4,5,6,7,8,9-octahydro-3H-azecino<5,4-b>indol-8-carbonsaeuremethylester 
• 128432-28-0 5-(3-Benzyloxypropyl)-3,8-methano-1,2,4,5,6,7,8,9-octahydro-3H-azecino<5,4-b>indol-14-on 
• 107688-36-8 3-(3-Benzyloxypropyl)-1,2,3,4,6,7,12,12b-octahydroindolo<2,3-a>quinolizin 

Relevant academic research and scientific papers

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS

This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1–R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.

Process for the preparation of the PPAR alpha agonist NS-220

The present invention is concerned with a novel process for the preparation of compounds of formula (I) wherein R1 and R2 are as defined in the description and claims. The compounds of formula (I) are pharmaceutically active substanc

Synthesis of extremely simplified compounds possessing the key pharmacophore units of taxol, phenylisoserine and oxetane moieties

Straight chain compounds having a phenylisoserine unit and an oxetane ring at the α- and ω- position, respectively as extremely simplified analogues of taxol were prepared. None of these compounds showed promising tubulin inhibitory activity.

The Synthesis of Octacidomycin

The total synthesis of octacidomycin (1), a novel oligocarboxylic acid antibiotic, and some shorter new model acids (19, 21, 24) is described.Key compounds in a series of fragment condensations of C19-, C5- and C2-units are α,α'-bis(bromopentyl)-substituted azealic- (6) and 3-(benzyloxypropyl)malonic esters (7).A six step synthesis yields bacteriostatically active octacidomycin (14=1). 14 and its octamethyl ester 15 are identical with the native products in all chemical and spectroscopic properties.Further combinations of fragments give tri-, tetra-, and pentacarboxylic acids.These demonstrate the flexibility of this widely variable synthetic method leading to new carboxylic acids and hydrocarbons.